Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 252

1.

The Lambda Select cII Mutation Detection System.

Besaratinia A, Tommasi S.

J Vis Exp. 2018 Apr 26;(134). doi: 10.3791/57510.

PMID:
29757290
2.

The search for a melanoma-tailored chemotherapy in the new era of personalized therapy: a phase II study of chemo-modulating temozolomide followed by fotemustine and a cooperative study of GOIM (Gruppo Oncologico Italia Meridionale).

Guida M, Tommasi S, Strippoli S, Natalicchio MI, De Summa S, Pinto R, Cramarossa A, Albano A, Pisconti S, Aieta M, Ridolfi R, Azzariti A, Guida G, Lorusso V, Colucci G.

BMC Cancer. 2018 May 10;18(1):552. doi: 10.1186/s12885-018-4479-2.

3.

CTLA-4 gene variant -1661A>G may predict the onset of endocrine adverse events in metastatic melanoma patients treated with ipilimumab.

Queirolo P, Dozin B, Morabito A, Banelli B, Carosio R, Fontana V, Ferrucci PF, Martinoli C, Cocorocchio E, Ascierto PA, Madonna G, Simeone E, De Galitiis F, Antonini Cappellini GC, Marchetti P, Guida M, Tommasi S, Ghilardi L, Merelli B, Fava P, Osella-Abate S, Guidoboni M, Romani M, Ferone D, Spagnolo F, Pistillo MP; Italian Melanoma Intergroup (IMI).

Eur J Cancer. 2018 Jul;97:59-61. doi: 10.1016/j.ejca.2018.04.005. Epub 2018 May 7. No abstract available.

PMID:
29743138
4.

Sex Differences in the Associations between L-Arginine Pathway Metabolites, Skeletal Muscle Mass and Function, and their Responses to Resistance Exercise, in Old Age.

Da Boit M, Tommasi S, Elliot D, Zinellu A, Sotgia S, Sibson R, Meakin JR, Aspden RM, Carru C, Mangoni AA, Gray SR.

J Nutr Health Aging. 2018;22(4):534-540. doi: 10.1007/s12603-017-0964-6.

PMID:
29582894
5.

Immunological mutational signature in adenosquamous cancer of pancreas: an exploratory study of potentially therapeutic targets.

Silvestris N, Brunetti O, Pinto R, Petriella D, Argentiero A, Fucci L, Tommasi S, Danza K, De Summa S.

Expert Opin Ther Targets. 2018 May;22(5):453-461. doi: 10.1080/14728222.2018.1456530. Epub 2018 Mar 27.

PMID:
29561217
6.

Corrigendum: Association of CTLA-4 Gene Variants with Response to Therapy and Long-term Survival in Metastatic Melanoma Patients Treated with Ipilimumab: An Italian Melanoma Intergroup Study.

Queirolo P, Dozin B, Morabito A, Banelli B, Piccioli P, Fava C, Leo C, Carosio R, Laurent S, Fontana V, Ferrucci PF, Martinoli C, Cocorocchio E, Battaglia A, Ascierto PA, Capone M, Simeone E, De Galitiis F, Pagani E, Antonini Cappellini GC, Marchetti P, Guida M, Tommasi S, Mandalà M, Merelli B, Quaglino P, Fava P, Guidoboni M, Romani M, Spagnolo F, Pistillo MP.

Front Immunol. 2018 Mar 2;9:403. doi: 10.3389/fimmu.2018.00403. eCollection 2018.

7.

Homoarginine and inhibition of human arginase activity: kinetic characterization and biological relevance.

Tommasi S, Elliot DJ, Da Boit M, Gray SR, Lewis BC, Mangoni AA.

Sci Rep. 2018 Feb 27;8(1):3697. doi: 10.1038/s41598-018-22099-x.

8.

Mutation Analysis in Cultured Cells of Transgenic Rodents.

Besaratinia A, Zheng A, Bates SE, Tommasi S.

Int J Mol Sci. 2018 Jan 16;19(1). pii: E262. doi: 10.3390/ijms19010262. Review.

9.

A possible role of FANCM mutations in male breast cancer susceptibility: Results from a multicenter study in Italy.

Silvestri V, Rizzolo P, Zelli V, Valentini V, Zanna I, Bianchi S, Tibiletti MG, Varesco L, Russo A, Tommasi S, Coppa A, Capalbo C, Calistri D, Viel A, Cortesi L, Manoukian S, Bonanni B, Montagna M, Palli D, Radice P, Peterlongo P, Ottini L.

Breast. 2018 Apr;38:92-97. doi: 10.1016/j.breast.2017.12.013. Epub 2018 Jan 4.

PMID:
29287190
10.

Adipokines in hereditary breast cancer patients and healthy relatives.

Sambiasi D, Summa S, Digennaro M, Pilato B, Paradiso A, Tommasi S.

Oncotarget. 2017 Sep 18;8(60):101255-101261. doi: 10.18632/oncotarget.21018. eCollection 2017 Nov 24.

11.

Angiogenesis in adenosquamous cancer of pancreas.

Silvestris N, Danza K, Longo V, Brunetti O, Fucci L, Argentiero A, Calabrese A, Cataldo I, Tamma R, Ribatti D, Tommasi S.

Oncotarget. 2017 Sep 27;8(56):95773-95779. doi: 10.18632/oncotarget.21319. eCollection 2017 Nov 10.

12.

Limited mutagenicity of electronic cigarettes in mouse or human cells in vitro.

Tommasi S, Bates SE, Behar RZ, Talbot P, Besaratinia A.

Lung Cancer. 2017 Oct;112:41-46. doi: 10.1016/j.lungcan.2017.07.035. Epub 2017 Aug 3.

PMID:
29191599
13.

MiR-193b regulates breast cancer cell migration and vasculogenic mimicry by targeting dimethylarginine dimethylaminohydrolase 1.

Hulin JA, Tommasi S, Elliot D, Hu DG, Lewis BC, Mangoni AA.

Sci Rep. 2017 Oct 25;7(1):13996. doi: 10.1038/s41598-017-14454-1.

14.

A Comparative Assessment of Quality of Life in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation Through an Outpatient and Inpatient Model.

Martino M, Ciavarella S, De Summa S, Russo L, Meliambro N, Imbalzano L, Gallo GA, Moscato T, Messina G, Ferreri A, Cuzzola M, Irrera G, Naso V, Cimminiello M, Console G, Loseto G, Tommasi S, Guarini A.

Biol Blood Marrow Transplant. 2018 Mar;24(3):608-613. doi: 10.1016/j.bbmt.2017.09.021. Epub 2017 Oct 13.

PMID:
29032271
15.

Six low-penetrance SNPs for the estimation of breast cancer heritability: A family-based study in Caucasian Italian patients.

De Summa S, Graziano F, Pilato B, Pinto R, Danza K, Lacalamita R, Serratì S, Sambiasi D, Grassi M, Tommasi S.

Oncol Lett. 2017 Oct;14(4):4384-4390. doi: 10.3892/ol.2017.6725. Epub 2017 Aug 4.

16.

Methotrexate, blood pressure and markers of arterial function in patients with rheumatoid arthritis: a repeated cross-sectional study.

Mangoni AA, Baghdadi LR, Shanahan EM, Wiese MD, Tommasi S, Elliot D, Woodman RJ.

Ther Adv Musculoskelet Dis. 2017 Sep;9(9):213-229. doi: 10.1177/1759720X17719850. Epub 2017 Aug 1.

17.

A Versatile Assay for Detection of Aberrant DNA Methylation in Bladder Cancer.

Tommasi S, Besaratinia A.

Methods Mol Biol. 2018;1655:29-41. doi: 10.1007/978-1-4939-7234-0_3.

PMID:
28889375
18.

TGFbeta and miRNA regulation in familial and sporadic breast cancer.

Danza K, Summa S, Pinto R, Pilato B, Palumbo O, Carella M, Popescu O, Digennaro M, Lacalamita R, Tommasi S.

Oncotarget. 2017 Jan 30;8(31):50715-50723. doi: 10.18632/oncotarget.14899. eCollection 2017 Aug 1.

19.

An opportune and unique research to evaluate the public health impact of electronic cigarettes.

Besaratinia A, Tommasi S.

Cancer Causes Control. 2017 Oct;28(10):1167-1171. doi: 10.1007/s10552-017-0952-5. Epub 2017 Aug 31.

PMID:
28861656
20.

VEGF and TWIST1 in a 16-biomarker immunoprofile useful for prognosis of breast cancer patients.

Schirosi L, De Summa S, Tommasi S, Paradiso A, Gasparini G, Popescu O, Simone G, Mangia A.

Int J Cancer. 2017 Nov 1;141(9):1901-1911. doi: 10.1002/ijc.30868. Epub 2017 Jul 20.

PMID:
28677228
21.
22.

Hereditary and non-hereditary branches of family eligible for BRCA test: cancers in other sites.

Digennaro M, Sambiasi D, Tommasi S, Pilato B, Diotaiuti S, Kardhashi A, Trojano G, Tufaro A, Paradiso AV.

Hered Cancer Clin Pract. 2017 May 25;15:7. doi: 10.1186/s13053-017-0067-8. eCollection 2017.

23.

Prediction of Breast and Prostate Cancer Risks in Male BRCA1 and BRCA2 Mutation Carriers Using Polygenic Risk Scores.

Lecarpentier J, Silvestri V, Kuchenbaecker KB, Barrowdale D, Dennis J, McGuffog L, Soucy P, Leslie G, Rizzolo P, Navazio AS, Valentini V, Zelli V, Lee A, Amin Al Olama A, Tyrer JP, Southey M, John EM, Conner TA, Goldgar DE, Buys SS, Janavicius R, Steele L, Ding YC, Neuhausen SL, Hansen TVO, Osorio A, Weitzel JN, Toss A, Medici V, Cortesi L, Zanna I, Palli D, Radice P, Manoukian S, Peissel B, Azzollini J, Viel A, Cini G, Damante G, Tommasi S, Peterlongo P, Fostira F, Hamann U, Evans DG, Henderson A, Brewer C, Eccles D, Cook J, Ong KR, Walker L, Side LE, Porteous ME, Davidson R, Hodgson S, Frost D, Adlard J, Izatt L, Eeles R, Ellis S, Tischkowitz M; EMBRACE, Godwin AK, Meindl A, Gehrig A, Dworniczak B, Sutter C, Engel C, Niederacher D, Steinemann D, Hahnen E, Hauke J, Rhiem K, Kast K, Arnold N, Ditsch N, Wang-Gohrke S, Wappenschmidt B, Wand D, Lasset C, Stoppa-Lyonnet D, Belotti M, Damiola F, Barjhoux L, Mazoyer S; GEMO Study Collaborators, Van Heetvelde M, Poppe B, De Leeneer K, Claes KBM, de la Hoya M, Garcia-Barberan V, Caldes T, Perez Segura P, Kiiski JI, Aittomäki K, Khan S, Nevanlinna H, van Asperen CJ; HEBON, Vaszko T, Kasler M, Olah E, Balmaña J, Gutiérrez-Enríquez S, Diez O, Teulé A, Izquierdo A, Darder E, Brunet J, Del Valle J, Feliubadalo L, Pujana MA, Lazaro C, Arason A, Agnarsson BA, Johannsson OT, Barkardottir RB, Alducci E, Tognazzo S, Montagna M, Teixeira MR, Pinto P, Spurdle AB, Holland H; KConFab Investigators, Lee JW, Lee MH, Lee J, Kim SW, Kang E, Kim Z, Sharma P, Rebbeck TR, Vijai J, Robson M, Lincoln A, Musinsky J, Gaddam P, Tan YY, Berger A, Singer CF, Loud JT, Greene MH, Mulligan AM, Glendon G, Andrulis IL, Toland AE, Senter L, Bojesen A, Nielsen HR, Skytte AB, Sunde L, Jensen UB, Pedersen IS, Krogh L, Kruse TA, Caligo MA, Yoon SY, Teo SH, von Wachenfeldt A, Huo D, Nielsen SM, Olopade OI, Nathanson KL, Domchek SM, Lorenchick C, Jankowitz RC, Campbell I, James P, Mitchell G, Orr N, Park SK, Thomassen M, Offit K, Couch FJ, Simard J, Easton DF, Chenevix-Trench G, Schmutzler RK, Antoniou AC, Ottini L.

J Clin Oncol. 2017 Jul 10;35(20):2240-2250. doi: 10.1200/JCO.2016.69.4935. Epub 2017 Apr 27.

24.

Association of CTLA-4 Gene Variants with Response to Therapy and Long-term Survival in Metastatic Melanoma Patients Treated with Ipilimumab: An Italian Melanoma Intergroup Study.

Queirolo P, Dozin B, Morabito A, Banelli B, Piccioli P, Fava C, Leo C, Carosio R, Laurent S, Fontana V, Ferrucci PF, Martinoli C, Cocorocchio E, Battaglia A, Ascierto PA, Capone M, Simeone E, De Galitiis F, Pagani E, Antonini Cappellini GC, Marchetti P, Guida M, Tommasi S, Mandalà M, Merelli B, Quaglino P, Fava P, Guidoboni M, Romani M, Spagnolo F, Pistillo MP.

Front Immunol. 2017 Apr 12;8:386. doi: 10.3389/fimmu.2017.00386. eCollection 2017. Erratum in: Front Immunol. 2018 Mar 02;9:403.

25.

Comment on 'Renewed interest in the progesterone receptor in breast cancer'.

Simone G, Diotaiuti S, Digennaro M, Sambiasi D, De Summa S, Tommasi S, Altieri R, Mangia A, Dantona C, Paradiso A.

Br J Cancer. 2017 Jul 11;117(2):e1. doi: 10.1038/bjc.2017.90. Epub 2017 Apr 11. No abstract available.

26.

GATK hard filtering: tunable parameters to improve variant calling for next generation sequencing targeted gene panel data.

De Summa S, Malerba G, Pinto R, Mori A, Mijatovic V, Tommasi S.

BMC Bioinformatics. 2017 Mar 23;18(Suppl 5):119. doi: 10.1186/s12859-017-1537-8.

27.

u-PAR expression in cancer associated fibroblast: new acquisitions in multiple myeloma progression.

Ciavarella S, Laurenzana A, De Summa S, Pilato B, Chillà A, Lacalamita R, Minoia C, Margheri F, Iacobazzi A, Rana A, Merchionne F, Fibbi G, Del Rosso M, Guarini A, Tommasi S, Serratì S.

BMC Cancer. 2017 Mar 24;17(1):215. doi: 10.1186/s12885-017-3183-y.

28.

Next-generation sequencing: advances and applications in cancer diagnosis.

Serratì S, De Summa S, Pilato B, Petriella D, Lacalamita R, Tommasi S, Pinto R.

Onco Targets Ther. 2016 Dec 2;9:7355-7365. eCollection 2016. Review.

29.

Genetic profiling of a rare condition: co-occurrence of albinism and multiple primary melanoma in a Caucasian family.

De Summa S, Guida M, Tommasi S, Strippoli S, Pellegrini C, Fargnoli MC, Pilato B, Natalicchio I, Guida G, Pinto R.

Oncotarget. 2017 May 2;8(18):29751-29759. doi: 10.18632/oncotarget.12777.

30.

β-catenin interaction with NHERF1 and RASSF1A methylation in metastatic colorectal cancer patients.

Schirosi L, Mazzotta A, Opinto G, Pinto R, Graziano G, Tommasi S, Fucci L, Simone G, Mangia A.

Oncotarget. 2016 Oct 18;7(42):67841-67850. doi: 10.18632/oncotarget.12280.

31.

Somatic alterations of targetable oncogenes are frequently observed in BRCA1/2 mutation negative male breast cancers.

Rizzolo P, Navazio AS, Silvestri V, Valentini V, Zelli V, Zanna I, Masala G, Bianchi S, Scarnò M, Tommasi S, Palli D, Ottini L.

Oncotarget. 2016 Nov 8;7(45):74097-74106. doi: 10.18632/oncotarget.12272.

32.

Breast cancer genome and transcriptome integration implicates specific mutational signatures with immune cell infiltration.

Smid M, Rodríguez-González FG, Sieuwerts AM, Salgado R, Prager-Van der Smissen WJ, Vlugt-Daane MV, van Galen A, Nik-Zainal S, Staaf J, Brinkman AB, van de Vijver MJ, Richardson AL, Fatima A, Berentsen K, Butler A, Martin S, Davies HR, Debets R, Gelder ME, van Deurzen CH, MacGrogan G, Van den Eynden GG, Purdie C, Thompson AM, Caldas C, Span PN, Simpson PT, Lakhani SR, Van Laere S, Desmedt C, Ringnér M, Tommasi S, Eyford J, Broeks A, Vincent-Salomon A, Futreal PA, Knappskog S, King T, Thomas G, Viari A, Langerød A, Børresen-Dale AL, Birney E, Stunnenberg HG, Stratton M, Foekens JA, Martens JW.

Nat Commun. 2016 Sep 26;7:12910. doi: 10.1038/ncomms12910.

33.

EMSY copy number variation in male breast cancers characterized for BRCA1 and BRCA2 mutations.

Navazio AS, Rizzolo P, Silvestri V, Valentini V, Zelli V, Zanna I, Masala G, Bianchi S, Tommasi S, Palli D, Ottini L.

Breast Cancer Res Treat. 2016 Nov;160(1):181-186. Epub 2016 Sep 15.

PMID:
27628328
34.

New insight into the role of metabolic reprogramming in melanoma cells harboring BRAF mutations.

Ferretta A, Maida I, Guida S, Azzariti A, Porcelli L, Tommasi S, Zanna P, Cocco T, Guida M, Guida G.

Biochim Biophys Acta. 2016 Nov;1863(11):2710-2718. doi: 10.1016/j.bbamcr.2016.08.007. Epub 2016 Aug 16.

35.

Detrimental effects of melanocortin-1 receptor (MC1R) variants on the clinical outcomes of BRAF V600 metastatic melanoma patients treated with BRAF inhibitors.

Guida M, Strippoli S, Ferretta A, Bartolomeo N, Porcelli L, Maida I, Azzariti A, Tommasi S, Grieco C, Guida S, Albano A, Lorusso V, Guida G.

Pigment Cell Melanoma Res. 2016 Nov;29(6):679-687. doi: 10.1111/pcmr.12516.

PMID:
27540956
36.

miR-151-5p, targeting chromatin remodeler SMARCA5, as a marker for the BRCAness phenotype.

Tommasi S, Pinto R, Danza K, Pilato B, Palumbo O, Micale L, De Summa S.

Oncotarget. 2016 Dec 6;7(49):80363-80372. doi: 10.18632/oncotarget.10345.

37.

BRCA1-2 diagnostic workflow from next-generation sequencing technologies to variant identification and final report.

Pilato B, Pinto R, De Summa S, Petriella D, Lacalamita R, Danza K, Paradiso A, Tommasi S.

Genes Chromosomes Cancer. 2016 Oct;55(10):803-13. doi: 10.1002/gcc.22383. Epub 2016 Jul 4.

PMID:
27225819
38.

Inhibitors of the Hydrolytic Enzyme Dimethylarginine Dimethylaminohydrolase (DDAH): Discovery, Synthesis and Development.

Murphy RB, Tommasi S, Lewis BC, Mangoni AA.

Molecules. 2016 May 11;21(5). pii: E615. doi: 10.3390/molecules21050615. Review.

39.

Landscape of somatic mutations in 560 breast cancer whole-genome sequences.

Nik-Zainal S, Davies H, Staaf J, Ramakrishna M, Glodzik D, Zou X, Martincorena I, Alexandrov LB, Martin S, Wedge DC, Van Loo P, Ju YS, Smid M, Brinkman AB, Morganella S, Aure MR, Lingjærde OC, Langerød A, Ringnér M, Ahn SM, Boyault S, Brock JE, Broeks A, Butler A, Desmedt C, Dirix L, Dronov S, Fatima A, Foekens JA, Gerstung M, Hooijer GK, Jang SJ, Jones DR, Kim HY, King TA, Krishnamurthy S, Lee HJ, Lee JY, Li Y, McLaren S, Menzies A, Mustonen V, O'Meara S, Pauporté I, Pivot X, Purdie CA, Raine K, Ramakrishnan K, Rodríguez-González FG, Romieu G, Sieuwerts AM, Simpson PT, Shepherd R, Stebbings L, Stefansson OA, Teague J, Tommasi S, Treilleux I, Van den Eynden GG, Vermeulen P, Vincent-Salomon A, Yates L, Caldas C, van't Veer L, Tutt A, Knappskog S, Tan BK, Jonkers J, Borg Å, Ueno NT, Sotiriou C, Viari A, Futreal PA, Campbell PJ, Span PN, Van Laere S, Lakhani SR, Eyfjord JE, Thompson AM, Birney E, Stunnenberg HG, van de Vijver MJ, Martens JW, Børresen-Dale AL, Richardson AL, Kong G, Thomas G, Stratton MR.

Nature. 2016 Jun 2;534(7605):47-54. doi: 10.1038/nature17676. Epub 2016 May 2.

40.

The next generation of metastatic melanoma: uncovering the genetic variants for anti-BRAF therapy response.

Pinto R, De Summa S, Strippoli S, Pilato B, Azzariti A, Guida G, Guida M, Tommasi S.

Oncotarget. 2016 May 3;7(18):25135-49. doi: 10.18632/oncotarget.7175.

41.

Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2.

Silvestri V, Barrowdale D, Mulligan AM, Neuhausen SL, Fox S, Karlan BY, Mitchell G, James P, Thull DL, Zorn KK, Carter NJ, Nathanson KL, Domchek SM, Rebbeck TR, Ramus SJ, Nussbaum RL, Olopade OI, Rantala J, Yoon SY, Caligo MA, Spugnesi L, Bojesen A, Pedersen IS, Thomassen M, Jensen UB, Toland AE, Senter L, Andrulis IL, Glendon G, Hulick PJ, Imyanitov EN, Greene MH, Mai PL, Singer CF, Rappaport-Fuerhauser C, Kramer G, Vijai J, Offit K, Robson M, Lincoln A, Jacobs L, Machackova E, Foretova L, Navratilova M, Vasickova P, Couch FJ, Hallberg E, Ruddy KJ, Sharma P, Kim SW; kConFab Investigators, Teixeira MR, Pinto P, Montagna M, Matricardi L, Arason A, Johannsson OT, Barkardottir RB, Jakubowska A, Lubinski J, Izquierdo A, Pujana MA, Balmaña J, Diez O, Ivady G, Papp J, Olah E, Kwong A; Hereditary Breast and Ovarian Cancer Research Group Netherlands (HEBON), Nevanlinna H, Aittomäki K, Perez Segura P, Caldes T, Van Maerken T, Poppe B, Claes KB, Isaacs C, Elan C, Lasset C, Stoppa-Lyonnet D, Barjhoux L, Belotti M, Meindl A, Gehrig A, Sutter C, Engel C, Niederacher D, Steinemann D, Hahnen E, Kast K, Arnold N, Varon-Mateeva R, Wand D, Godwin AK, Evans DG, Frost D, Perkins J, Adlard J, Izatt L, Platte R, Eeles R, Ellis S; EMBRACE, Hamann U, Garber J, Fostira F, Fountzilas G, Pasini B, Giannini G, Rizzolo P, Russo A, Cortesi L, Papi L, Varesco L, Palli D, Zanna I, Savarese A, Radice P, Manoukian S, Peissel B, Barile M, Bonanni B, Viel A, Pensotti V, Tommasi S, Peterlongo P, Weitzel JN, Osorio A, Benitez J, McGuffog L, Healey S, Gerdes AM, Ejlertsen B, Hansen TV, Steele L, Ding YC, Tung N, Janavicius R, Goldgar DE, Buys SS, Daly MB, Bane A, Terry MB, John EM, Southey M, Easton DF, Chenevix-Trench G, Antoniou AC, Ottini L.

Breast Cancer Res. 2016 Feb 9;18(1):15. doi: 10.1186/s13058-016-0671-y.

42.

Role of miR-27a, miR-181a and miR-20b in gastric cancer hypoxia-induced chemoresistance.

Danza K, Silvestris N, Simone G, Signorile M, Saragoni L, Brunetti O, Monti M, Mazzotta A, De Summa S, Mangia A, Tommasi S.

Cancer Biol Ther. 2016 Apr 2;17(4):400-6. doi: 10.1080/15384047.2016.1139244.

43.

miRNA profiling in serum and tissue samples to assess noninvasive biomarkers for NSCLC clinical outcome.

Petriella D, De Summa S, Lacalamita R, Galetta D, Catino A, Logroscino AF, Palumbo O, Carella M, Zito FA, Simone G, Tommasi S.

Tumour Biol. 2016 Apr;37(4):5503-13. doi: 10.1007/s13277-015-4391-1. Epub 2015 Nov 13.

PMID:
26566629
44.

Expression of epigenetic modifiers is not significantly altered by exposure to secondhand smoke.

Tommasi S, Zheng A, Besaratinia A.

Lung Cancer. 2015 Dec;90(3):598-603. doi: 10.1016/j.lungcan.2015.10.023. Epub 2015 Oct 27.

PMID:
26525280
45.

Arginine analogues incorporating carboxylate bioisosteric functions are micromolar inhibitors of human recombinant DDAH-1.

Tommasi S, Zanato C, Lewis BC, Nair PC, Dall'Angelo S, Zanda M, Mangoni AA.

Org Biomol Chem. 2015 Dec 14;13(46):11315-30. doi: 10.1039/c5ob01843a. Epub 2015 Sep 30.

PMID:
26420019
46.

Immunoprofile from tissue microarrays to stratify familial breast cancer patients.

Schirosi L, De Summa S, Tommasi S, Paradiso A, Sambiasi D, Popescu O, Simone G, Mangia A.

Oncotarget. 2015 Sep 29;6(29):27865-79. doi: 10.18632/oncotarget.4720.

47.

Novel and known genetic variants for male breast cancer risk at 8q24.21, 9p21.3, 11q13.3 and 14q24.1: results from a multicenter study in Italy.

Silvestri V, Rizzolo P, Scarnò M, Chillemi G, Navazio AS, Valentini V, Zelli V, Zanna I, Saieva C, Masala G, Bianchi S, Manoukian S, Barile M, Pensotti V, Peterlongo P, Varesco L, Tommasi S, Russo A, Giannini G, Cortesi L, Viel A, Montagna M, Radice P, Palli D, Ottini L.

Eur J Cancer. 2015 Nov;51(16):2289-95. doi: 10.1016/j.ejca.2015.07.020. Epub 2015 Aug 3.

PMID:
26248686
48.

MicroRNA expression in BRAF-mutated and wild-type metastatic melanoma and its correlation with response duration to BRAF inhibitors.

Pinto R, Strippoli S, De Summa S, Albano A, Azzariti A, Guida G, Popescu O, Lorusso V, Guida M, Tommasi S.

Expert Opin Ther Targets. 2015;19(8):1027-35.

PMID:
26156293
49.

FANCM c.5791C>T nonsense mutation (rs144567652) induces exon skipping, affects DNA repair activity and is a familial breast cancer risk factor.

Peterlongo P, Catucci I, Colombo M, Caleca L, Mucaki E, Bogliolo M, Marin M, Damiola F, Bernard L, Pensotti V, Volorio S, Dall'Olio V, Meindl A, Bartram C, Sutter C, Surowy H, Sornin V, Dondon MG, Eon-Marchais S, Stoppa-Lyonnet D, Andrieu N, Sinilnikova OM; GENESIS, Mitchell G, James PA, Thompson E; kConFab; SWE-BRCA, Marchetti M, Verzeroli C, Tartari C, Capone GL, Putignano AL, Genuardi M, Medici V, Marchi I, Federico M, Tognazzo S, Matricardi L, Agata S, Dolcetti R, Della Puppa L, Cini G, Gismondi V, Viassolo V, Perfumo C, Mencarelli MA, Baldassarri M, Peissel B, Roversi G, Silvestri V, Rizzolo P, Spina F, Vivanet C, Tibiletti MG, Caligo MA, Gambino G, Tommasi S, Pilato B, Tondini C, Corna C, Bonanni B, Barile M, Osorio A, Benitez J, Balestrino L, Ottini L, Manoukian S, Pierotti MA, Renieri A, Varesco L, Couch FJ, Wang X, Devilee P, Hilbers FS, van Asperen CJ, Viel A, Montagna M, Cortesi L, Diez O, Balmaña J, Hauke J, Schmutzler RK, Papi L, Pujana MA, Lázaro C, Falanga A, Offit K, Vijai J, Campbell I, Burwinkel B, Kvist A, Ehrencrona H, Mazoyer S, Pizzamiglio S, Verderio P, Surralles J, Rogan PK, Radice P.

Hum Mol Genet. 2015 Sep 15;24(18):5345-55. doi: 10.1093/hmg/ddv251. Epub 2015 Jun 30.

50.

Metastatic melanoma cells with BRAF G469A mutation: nab-paclitaxel better than vemurafenib?

Porcelli L, Guida G, Tommasi S, Guida M, Azzariti A.

Cancer Chemother Pharmacol. 2015 Aug;76(2):433-8. doi: 10.1007/s00280-015-2796-6. Epub 2015 Jun 13.

PMID:
26070258

Supplemental Content

Loading ...
Support Center